Your Directors are pleased to present their 52^nd Annual Report on the business and operations together with the Audited
Financial Statements of the Company for financial year ended 31 March, 2026. Consolidated performance of the Company
and its subsidiaries has been referred to, wherever required

FINANCIAL PERFORMANCE

OVERVIEW OF FINANCIAL PERFORMANCE

During financial year ended 31 March, 2026, the Company's total revenue including other income was C 102,190.8 Million on
Standalone basis as against C 93,205.0 Million achieved in the previous year, registering a growth of 9.6 %.

The export turnover of the Company during financial year 2025-26 was C 26,405 Million as against C 24,908.3 Million achieved
in the previous year, registering a growth of 6.0 %.

During financial year ended 31 March, 2026, the Company
and its subsidiaries achieved a total revenue including other
income of C 152,956.2 Million on Consolidated basis, as
against a turnover of C 134,582.6 Million achieved in the
previous year, registering a growth of 13.7 %.

During financial year ended 31 March, 2026, Standalone
Profit before exceptional items, interest, depreciation
and tax from continuing operations increased by 11.9 %
at C 29,795.6 Million as against C 26,632.6 Million in
the previous year, whereas Consolidated Profit before
exceptional items, interest, depreciation and tax increased
by 19.4 % at C 35,885.6 Million as against C 30,058.9 Million
in the previous year. As a result, Standalone Profit before
tax increased by 9.5 % over the previous year to C 25,226.2
Million and Consolidated Profit before tax was C 28,708.9
Million, which grew by 13.6 % over the previous year.

The Standalone Net Profit after tax for financial year ended
31 March, 2026 increased by 4.6 % to C 21,851.2 Million
over the previous year while the Consolidated Net Profit after
tax increased by 6.3% over the previous year to C 23,018.0
Million.

DIVIDEND

During financial year 2025-26, the Board of Directors on
13 February, 2026, declared and paid an interim dividend
of C 43/- (Rupees Forty Three only) per equity share of
C 2/- (Rupees Two only) each, being 2150% of paid up share
capital of the Company. In addition, your Directors are
pleased to recommend payment of C 10/- (Rupees Ten only)
per equity share of C 2/- (Rupees Two only) each as final
dividend for financial year 2025-26, for the approval of the
Members at the ensuing Annual General Meeting (AGM) of
the Company. If approved, the total dividend (interim and
final) for financial year 2025-26 will be C 53/- (Rupees Fifty
Three only) per equity share of C 2/- (Rupees Two only) each
as against the total dividend of C 45/- (Rupees Forty Five
only) per equity share of C 2/- (Rupees Two only) each paid
for the previous financial year.

In compliance with the requirement of Regulation 43A of
the SEBI (Listing Obligation and Disclosure Requirements)
Regulations, 2015 (hereinafter referred to as “SEBI LODR
Regulations”), the Company has formulated its Dividend
Distribution Policy, which is available on the Company's website
at https://admin.alkemlabs.com/uploads/977928327
Dividend distribution policy 6b026313dc.pdf

The said Policy is also annexed to this Report as Annexure A.

TRANSFER TO RESERVES

The Board does not propose to transfer any amount to the
General Reserve for financial year 2025-26.

SHARE CAPITAL

The paid up equity share capital of the Company as on
31 March, 2026 was C 239.1 Million. The Company has neither
issued shares with differential rights as to dividend, voting or
otherwise nor issued shares to the Employees or Directors
of the Company, under any scheme (including sweat equity
shares).

DEPOSITS

The Company has not accepted any deposits from the public/
members during the year under review and accordingly no
amount on account of principal or interest on public deposits
was outstanding as on 31 March, 2026.

SUBSIDIARIES

As on 31 March, 2026, the Company has a total of 33
subsidiaries and 2 associate companies within the meaning
of Sections 2(87) and 2(6) of the Companies Act, 2013
(hereinafter referred to as “the Act”) respectively. The
Company does not have any joint venture company(ies).

During the year under review:

• Acquired 100% stake of M/s. Bombay Ortho Industries
Private Limited through M/s. Alkem Medtech Private
Limited, thereby making it a Wholly-owned step-down
subsidiary of the Company w.e.f. 16 April, 2025.
Subsequently, the name of M/s. Bombay Ortho Industries
Private Limited was changed to ‘Alkem MedTech Ortho
Private Limited' w.e.f. 9 June, 2025;

• Acquired 100% stake of M/s. Adroit Biomed Limited,
thereby making it a Wholly-owned subsidiary of the
Company w.e.f. 23 April, 2025;

• M/s. Alkem Pharmaceuticals Scientific Office FZ-LLC
was incorporated as a Wholly-owned subsidiary of the
Company in Dubai, on 04 February, 2026;

• M/s. Alkem Pharma Trading FZCO was incorporated as
a Wholly-owned subsidiary of the Company in Dubai, on
27 March, 2026.

and none of the companies ceased to be a subsidiary of the
Company.

Pursuant to the first proviso to Section 129(3) of the Act and
Rule 5 and Rule 8(1) of the Companies (Accounts) Rules, 2014,
the salient features of financial statements, performance
and financial position of each subsidiary is given in Form
AOC-1 as Annexure B to this Report.

The Audited Financial Statements of the subsidiaries
are available on the Company’s website a https://www.
alkemlabs.com/investors/subsidiary-accounts pursuant to
Section 136 of the Act.

SCHEME OF MERGER

The Board of Directors of the Company has at its meeting held
on 13 February, 2026 approved the amalgamation of Adroit
Biomed Limited (“Transferor Company”), a wholly-owned
subsidiary of the Company with and into the Company by
way of a scheme of arrangement pursuant to the provisions
of Sections 230 to 232 and other applicable provisions of
the Companies Act, 2013 (including the rules thereunder)
(“Scheme”), and in compliance with the provisions of the
Income Tax Act.

The Scheme is, inter alia, subject to the sanction of the
Mumbai bench of the National Company Law Tribunal
(“NCLT”) and requisite approvals of the shareholders and/
or creditors of the Company, if so directed by the NCLT,
and subject to compliance with applicable laws or other
approvals, if required.

MANAGEMENT DISCUSSION AND ANALYSIS

A detailed report on the Management Discussion and
Analysis is provided as a separate section forming part of
this Report.

CORPORATE GOVERNANCE

In compliance with Regulation 34 read with Schedule V of the
SEBI LODR Regulations, a Report on Corporate Governance
for the year under review is provided as a separate section
along with a certificate from the Statutory Auditors
conforming the Company's compliance with the conditions
of Corporate Governance, forming part of this Report.

BUSINESS RESPONSIBILITY AND SUSTAINABILITY
REPORT

In compliance with Regulation 34 of SEBI LODR Regulations,
the Business Responsibility and Sustainability Report,
describing the initiatives taken by the Company from an
environmental, social and governance perspective, is
provided as a separate section forming part of this Report.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Company undertakes CSR activities in accordance with
the Company's CSR Policy. The CSR programme aims to
address the immediate and long term needs of the community
and focus on where the major impact on marginalized
sections of the society can be made. The Company's CSR
strategy involves a multi-sectoral inclusive approach to
focus on community needs. It strives to improve the well¬
being of communities by focusing on key thematic areas of
healthcare, education, rural development, environment and
sports. The Company implements these activities directly
or through reliable partnerships with various NGOs. During
financial year 2025-26, the Company has addressed the
requirements of local communities in the vicinity of its head
office, manufacturing facilities and R&D centers through
focused projects in the said thematic areas.

Details about the Company’s CSR Policy and initiatives
undertaken by the Company during financial year 2025-26
are outlined in the Report on CSR activities annexed to this
Report as Annexure C.

The CSR Policy is posted on Company’s website: https://
admin.alkemlabs.com/uploads/csr policy e0e5ec8d61.pdf

DIRECTORS AND KEY MANAGERIAL PERSONNEL
Appointments:

The details of the appointments during the year under review
are as follows:

Appointment of Mr. Ranjal Laxmana Shenoy as an
Independent Director of the Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high
standards of integrity possessed by Mr. Ranjal Laxmana
Shenoy (DIN: 00074761), the Board of Directors of the
Company based on recommendation of the Nomination
and Remuneration Committee and subject to approval of
the Members of the Company, approved the appointment
of Mr. Ranjal Laxmana Shenoy (DIN: 00074761) as an
Additional Director designated as an Independent Director
of the Company.

Thereafter, the Members of the Company through Postal
Ballot on 12 July,2025 approved the said appointment of
Mr. Ranjal Laxmana Shenoy as an Independent Director of
the Company, not liable to retire by rotation, for a term of
5 (five) consecutive years w.e.f. 13 July, 2025 upto 12 July,
2030.

Appointment of Ms. Neela Bhattacherjee as an Independent
Director of the Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high
standards of integrity possessed by Ms. Neela Bhattacherjee
(DIN: 01912483), the Board of Directors of the Company based
on recommendation of the Nomination and Remuneration
Committee and subject to approval of the Members of
the Company, approved the appointment of Ms. Neela
Bhattacherjee (DIN: 01912483) as an Additional Director
designated as an Independent Director of the Company.

Thereafter, the Members of the Company through Postal
Ballot on 12 July, 2025 approved the said appointment of
Ms. Neela Bhattacherjee as an Independent Director of the
Company, not liable to retire by rotation, for a term of 5 (five)
consecutive years w.e.f. 13 July, 2025 upto 12 July, 2030.

Appointment of Mr. Diwakar Gupta as an Independent
Director of the Company w.e.f. 13 July, 2025.

Considering the experience, expertise, proficiency and high
standards of integrity possessed by Mr. Diwakar Gupta (DIN:
01274552), the Board of Directors of the Company based
on recommendation of the Nomination and Remuneration

Committee and subject to approval of the Members of the
Company, approved the appointment of Mr. Diwakar Gupta
(DIN: 01274552) as an Additional Director designated as an
Independent Director of the Company.

The Members of the Company through Postal Ballot on 02
August, 2025 approved the said appointment of Mr. Diwakar
Gupta as an Independent Director of the Company, not liable
to retire by rotation, for a term of 5 (five) consecutive years
w.e.f. 13 July, 2025 upto 12 July, 2030.

Re-appointment:

Re-appointment of Mrs. Madhurima Singh, Executive
Director of the Company.

The Board of Directors of the Company based on the
recommendation of the Nomination and Remuneration
Committee and Audit Committee and pursuant to the relevant
provisions of SEBI LODR Regulations, Sections 196, 197 and
198 read with Schedule V and other applicable provisions
of the Act, the Articles of Association of the Company and
considering her contribution towards the growth of the
Company, approved the re-appointment of Mrs. Madhurima
Singh as an Executive Director of the Company for a term of
5 (five) consecutive years commencing from 20 December,
2026 upto 19 December, 2031 subject to the approval of the
Members of the Company.

Completion of tenure

Tenure Completion

Mr. Arun Kumar Purwar, Ms. Sangeeta Singh and Ms. Sudha
Ravi retired from the Board of Directors of the Company
after the close of business hours on 12 July, 2025, upon
completion of their second term as Independent Directors
of the Company. The Directors place on record their
appreciation on the contribution made by the above Directors
in the growth of the Company during their tenure.

Directors liable to retire by rotation

Mr. Sandeep Singh (DIN: 01277984) and Mr. Sarvesh Singh
(DIN: 01278229) are liable to retire by rotation at the ensuing
AGM of the Company pursuant to the provisions of Section
152 of the Act read with the Companies (Appointment and
Qualification of Directors) Rules, 2014 and the Articles
of Association of the Company and being eligible they
have offered themselves for re-appointment, on the
recommendation of the Nomination and Remuneration
Committee and the Board of Directors of the Company.

Particulars in pursuance of Regulation 36 of the SEBI LODR
Regulations read with Secretarial Standard - 2 on General
Meetings relating to Mr. Sandeep Singh and Mr. Sarvesh
Singh are given in the Notice of AGM.

Key Managerial Personnel

In accordance with the provisions of Section 203 of the Act
read with the Companies (Appointment and Remuneration
of Managerial Personnel) Rules, 2014 the following are

the Key Managerial Personnel of the Company as on
31 March, 2026:

• Mr. Sandeep Singh - Managing Director;

• Dr. Vikas Gupta - Chief Executive Officer (upto 30 June,

2026);

• Mr. Nitin Agrawal - President and Chief Financial Officer;
and

• Mr. Manish Narang, President - Legal, Company Secretary
and Compliance Office

Resignation

Dr. Vikas Gupta Chief Executive Officer and Key managerial
personnel of the Company, resigned w.e.f. 30 June, 2026 to
pursue new professional opportunities. The Directors placed
on record appreciation for the valuable contribution made
by Dr. Vikas Gupta during his tenure as a Chief Executive
Officer and Key managerial personnel in the Company.

Independent Directors

The Independent Directors hold office for a term of 5 (five)
years and are not liable to retire by rotation. The Independent
Directors of the Company fulfill the conditions specified in
the Act and SEBI LODR Regulations and are independent of
the management.

Declaration of independence from Independent
Directors

The Company has received declarations from all the
Independent Directors confirming that they meet the criteria
of independence as prescribed under the provisions of the
Act, read with the schedules and rules issued thereunder,
as well as Regulation 16(1)(b) of the SEBI LODR Regulations
(including any statutory modification(s) or re-enactment(s)
thereof for the time being in force). In terms of Regulation
25(8) of the SEBI LODR Regulations, the Independent Directors
have confirmed that they are not aware of any circumstance
or situation, which exist or may be reasonably anticipated,
that could impair or impact their ability to discharge their
duties with an objective independent judgement and without
any external influence.

The terms and conditions of appointment of the Independent
Directors are posted on Company's website: https://
admin.alkemlabs.com/uploads/Terms of appointment
Independent Directors 2a82f9dd72.pdf

Familiarisation Programme

In compliance with the requirements of SEBI LODR
Regulations, the Company has put in place a framework for
Directors' Familiarisation Programme to familiarize them
with their roles, rights and responsibilities as Directors, the
working of the Company, nature of the industry in which the
Company operates, business model, etc. The details of the
Familiarisation Programme conducted during financial year
under review are explained in the Corporate Governance

Report. The same is also available on the Company's
website at https://www.alkemlabs.com/investors/details-
familiarization-program .

Annual Evaluation of Board's Performance

The details of the annual evaluation of the Individual
Directors, Board as a whole and all the Committees of the
Board have been provided in the Corporate Governance
Report, which forms part of this Report.

The Independent Directors, at a separate meeting held
on 26 March, 2026 evaluated performance of Non¬
Independent Directors, performance of the Board as a whole
and performance of the Chairperson of the Company.

The evaluation of the Independent Directors was carried out
by the entire Board of Directors without the participation of
the respective Independent Director.

The Company follows a policy for selection and appointment
of Directors, Senior Management and their remuneration,
which is available on the Company's website at https://ad.min.
alkemlabs.com/uploads/1378936118 Nomination and
Remuneration Policy modified 27052016 307d64b304.
pdf. The said Policy is annexed to this Report as Annexure D.

PARTICULARS OF EMPLOYEES AND RELATED
DISCLOSURES

The disclosure pertaining to remuneration and other details
as required under Section 197(12) of the Act read with Rule
5(1) of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 is annexed to this Report
as Annexure E.

Further, a statement showing the names and other particulars
of top ten employees in terms of remuneration drawn and
of employees drawing remuneration in excess of the limits
required under Section 197(12) of the Act read with Rule 5(2)
and 5(3) of the Companies (Appointment and Remuneration
of Managerial Personnel) Rules, 2014 forms part of this
Report. However, in terms of first proviso to Section 136(1) of
the Act, the Annual Report and Annual Financial Statements
are being sent by email to the Members and others entitled
thereto, excluding the aforesaid information. The said
information shall be provided electronically to any Member
on a written request to the Company Secretary to obtain a
copy of the same.

NUMBER OF MEETINGS OF THE BOARD

The Board of Directors met 7 (seven) times during financial
year 2025-26. The details of the Board meetings and the
attendance of Directors thereat are provided in the Corporate
Governance Report, which forms part of this Report.

COMMITTEES OF THE BOARD

Audit Committee

As on 01 April, 2025, the Audit Committee comprised of
Mr. Arun Kumar Purwar as Chairperson and Mr. Sandeep
Singh, Mr. Mritunjay Kumar Singh, Ms. Sangeeta Singh,
Mr. Narendra Kumar Aneja and Ms. Sudha Ravi as Members.

Thereafter, the Board at its meeting held on 18 June, 2025,
reconstituted the Audit Committee with effect from
13 July, 2025, comprising of Mr. Narendra Kumar Aneja as
Chairperson and Mr. Sandeep Singh, Mr. Mritunjay Kumar
Singh, Mr. R. L. Shenoy, Mr. Rajeev Kher and Mr. Diwakar
Gupta as Members.

The brief terms of reference of the Audit Committee and the
particulars of meetings held and attendance thereat are
mentioned in the Corporate Governance Report which forms
part of this Report.

Nomination and Remuneration Committee

As on 01 April, 2025, the Nomination and Remuneration
Committee comprised of Mr. Arun Kumar Purwar as
Chairperson and Mr. Basudeo N. Singh, Ms. Sudha Ravi and
Mr. Narendra Kumar Aneja as Members.

Thereafter, the Board at its meeting held on 18 June, 2025
reconstituted the Nomination and Remuneration Committee
with effect from 13 July, 2025, comprising of Mr. R. L. Shenoy
as Chairperson and Mr. Basudeo N. Singh, Mr. Sujjain Talwar,
and Ms. Neela Bhattacherjee as Members.

The brief terms of reference of the Nomination and
Remuneration Committee and the particulars of meetings
held and attendance thereat are mentioned in the Corporate
Governance Report which forms part of this Report.

Corporate Social Responsibility and Sustainability
Committee

As on 01 April, 2025, the Corporate Social Responsibility
and Sustainability Committee comprised of Mrs. Madhurima
Singh as Chairperson and Mr. Sandeep Singh, Mr. Srinivas
Singh, Ms. Sangeeta Singh and Ms. Sudha Ravi as Members.

Thereafter, the Board at its meeting held on 18 June, 2025
reconstituted the Corporate Social Responsibility and
Sustainability Committee with effect from 13 July, 2025,
comprising of Mrs. Madhurima Singh as Chairperson and
Mr. Srinivas Singh, Mr. Sarvesh Singh, Mr. Narendra Kumar
Aneja and Mr. Rajeev Kher as Members.

The brief terms of reference of the Corporate Social
Responsibility and Sustainability Committee and the
particulars of meetings held and attendance thereat are
mentioned in the Corporate Governance Report which forms
part of this Report.

Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee comprises of
Mr. Sujjain Talwar as Chairperson and Mr. Mritunjay Kumar
Singh, Mrs. Madhurima Singh and Mr. Srinivas Singh as
Members.

The brief terms of reference of the Stakeholders'
Relationship Committee and the particulars of meetings
held and attendance thereat are mentioned in the Corporate
Governance Report which forms part of this Report.

Risk Management Committee

As on 01 April, 2025, the Risk Management Committee
comprised of Mr. Mritunjay Kumar Singh as Chairperson
and Mr. Sandeep Singh, Mr. Srinivas Singh, Ms. Sudha Ravi,
Mr. Narendra Kumar Aneja and Mr. Sujjain Talwar as Members.

Thereafter, the Board at its meeting held on 18 June, 2025
reconstituted the Risk Management Committee with effect
from 13 July, 2025, comprising of Mr. Mritunjay Kumar
Singh as Chairperson and Mr. Sandeep Singh, Mr. Srinivas
Singh, Ms. Neela Bhattacherjee, Mr. Diwakar Gupta and
Mr. R. L. Shenoy as Members.

The brief terms of reference of the Risk Management
Committee and the particulars of meeting held and
attendance thereat are mentioned in the Corporate
Governance Report which forms part of this Report.

RISK MANAGEMENT

The Company's Board of Directors has overall responsibility
for the establishment and oversight of the Company's
risk management framework. The Company has a
Board approved Risk Management Policy. The Board of
Directors has constituted a Risk Management Committee
which is delegated with the responsibility of overseeing
various strategic, operational and financial risks that the
organization faces, along with assessment of risks, their
management and mitigation procedures. A detailed analysis
of the business risks and opportunities is given under
Management Discussion and Analysis Report forming part
of this Report.

DIRECTORS’ RESPONSIBILITY STATEMENT

To the best of their knowledge and belief, your Directors
confirm that:

(a) i n the preparation of the annual accounts for financial
year ended 31 March, 2026, the applicable accounting
standards have been followed along with proper
explanation relating to material departures, if any;

(b) t hey have selected such accounting policies and applied
them consistently and made judgements and estimates
that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the Company as at
31 March, 2026 and of the profit of the Company for
the year ended on that date;

(c) t hey have taken proper and sufficient care for
the maintenance of adequate accounting records
in accordance with the provisions of the Act, for
safeguarding the assets of the Company and for
preventing and detecting fraud and other irregularities;

(d) t hey have prepared the annual financial statements on
a going concern basis;

(e) t hey have laid down internal financial controls to be
followed by the Company and that such internal financial
controls are adequate and operating effectively; and

(f) t hey have devised proper systems to ensure compliance
with the provisions of all applicable laws and that such
systems are adequate and operating effectively.

SECRETARIAL STANDARDS

The Company has devised proper systems to ensure
compliance with the provisions of all applicable Secretarial
Standards issued by the Institute of Company Secretaries
of India and that such systems are adequate and operating
effectively.

AUDITORS AND AUDITORS’ REPORT

Statutory Auditors

Pursuant to the provisions of Section 139 of the Act and the
Companies (Audit and Auditors) Rules, 2014 (including any
statutory modification(s) or re-enactment(s) thereof, for
the time being in force), M/s. Deloitte Haskins & Sells LLP
(Firm Registration No. 117366W/W-100018), Chartered
Accountants, the Statutory Auditors of the Company,
were appointed pursuant to the resolution passed by the
Shareholders at the 50^th AGM of the Company held on
30 August, 2024, for a term of 5 (five) consecutive years
from the conclusion of 50^th AGM of the Company until the
conclusion of the 55^th AGM to be held in year 2029.

M/s. Deloitte Haskins & Sells LLP, Chartered Accountants,
the Statutory Auditors of the Company have confirmed that
they are not disqualified from continuing as the Auditors of
the Company for financial year 2026-27.

The Auditors' Report for financial year ended 31 March, 2026,
is an unmodified one. However, pursuant to CARO report,
following adverse remark stated in the Auditor's report:

Delay in respect of remittance of Provident Fund and
Profession tax: The delay in remittance of Provident Fund (“PF”)
is attributable to the earlier process of initiating PF settlements
only after receipt of the completed Full & Final (F&F) Clearance
Form. To address this, the process has been revised with
effect from January 2026, whereby PF remittances have been
initiated immediately upon an employee's separation from
the Company. This has strengthened statutory compliance,
mitigated the risk of interest and penal liabilities, and ensured
timely remittance of dues going forward.There has been no
delay in respect of remittance of Profession tax.

Cost Auditor

The Company is required to maintain cost records for certain
products as specified by the Central Government under
Section 148(1) of the Act and accordingly such accounts and
records are made and maintained in the prescribed manner.

Pursuant to the provisions of Section 148 of the Act and the
rules made thereunder read with notifications/ circulars
issued by the Ministry of Corporate Affairs from time-to-
time and as per the recommendation of the Audit Committee,
the Board of Directors at its meeting held on 29 May, 2025,
had re-appointed Mr. Suresh D. Shenoy, Cost Accountant
(Membership No. 8318), as the Cost Auditor of the Company
for financial year 2025-26 to conduct the audit of the cost
records of the Company. A resolution for ratification of the
fees payable to the Cost Auditor is included in the Notice of
AGM for seeking approval of Members. The Cost Audit Report
will be filed within the period stipulated under the Act.

Secretarial Auditors

Pursuant to the provisions of Section 204 of the Act read
with the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014, the Board of Directors
had appointed M/s. Manish Ghia & Associates, Practicing
Company Secretaries, (Membership No. F6252, COP No.
3531) to conduct the Secretarial Audit of the Company for
a term of 5 (five) consecutive years to hold office w.e.f.
01 April, 2025 upto 31 March, 2030, on such fees as may
be decided by the Board of Directors of the Company and
the Secretarial Auditors. The said appointment was then
approved by the Shareholders at the 51^st Annual General
Meeting of the Company held on 25 August, 2025.

The Secretarial Audit Report received from M/s. Manish
Ghia & Associates, Secretarial Auditors of the Company,
for financial year ended 31 March, 2026 is annexed to this
Report as Annexure F. The said Report does not contain any
qualification, reservation or adverse remark.

ANNUAL RETURN

The Annual Return of the Company in prescribed Form MGT-
7 is available on the website of the Company at https://www.
alkemlabs.com/investors/annual-returns

RELATED PARTY TRANSACTIONS

All the Related Party Transactions entered into during
financial year 2025-26 by the Company, were at arm's length
basis and in compliance with the applicable provisions of the
Act and the SEBI LODR Regulations and are in conformity with
the Company's Policy on Related Party Transactions.

The disclosure of material related party transactions
entered into by the Company during financial year 2025-26,
as required under Section 134(3) (h) of the Act read with
Rule 8(2) of the Companies (Accounts) Rules, 2014 in
Form AOC-2 is annexed to this Report as Annexure G. The

Policy on Related Party Transactions as approved by the
Board of Directors is posted on the Company's website at
https://admin.alkemlabs.com/uploads/Related Party
Transactions Policy 1e79a77a4a.pdf

PARTICULARS OF LOANS/ GUARANTEES
GIVEN/ INVESTMENTS MADE AND
SECURITIES PROVIDED

The particulars of loans, guarantees, investments and
securities provided covered under the provisions of Section
186 of the Act have been disclosed in the notes to the financial
statements forming part of the Annual Report.

VIGIL MECHANISM / WHISTLE BLOWER
POLICY

Pursuant to the provisions of Section 177(9) of the Act, the
Board of Directors of the Company have framed the Vigil
Mechanism / Whistle Blower Policy for employees and/
or volunteers of the Company. The said Policy encourages
to report any action or suspected action taken within the
Company that is illegal, fraudulent or in violation of any
adopted policy of the Company including reporting of
instances of leak or suspected leak of unpublished price
sensitive information. The Policy also provides access to
the Chairperson of the Audit Committee under certain
circumstances. The Whistle Blower Policy is posted on the
website of the Company at https://admin.alkemlabs.com/
uploads/Whistle Blower Policy new 5d094b8491.pdf

PREVENTION OF SEXUAL HARASSMENT AT
WORKPLACE

The Company has adopted a policy fully in compliance
with the provisions of Sexual Harassment of Women at
Workplace (Prevention, Prohibition and Redressal) Act, 2013
and the Rules made thereunder.

Internal Complaints Committees have been set up at the head
office of the Company as well as at all the Company's plants,
depots and R&D centers to redress complaints received
on sexual harassment. The details of complaints received
during financial year 2025-26 are as under:

a. n umber of complaints of sexual harassment received
in the year: 2

b. number of complaints disposed off during the year: 2

c. n umber of cases pending for more than ninety days :
Nil

DISCLOSURES UNDER THE ACT

Change in Nature of Business, if any:

During financial year 2025-26, there has been no change in
the nature of business of the Company.

Material Changes and Commitments affecting the
financial position of the Company:

There are no material changes and commitments, which
have occurred between the end of financial year and the
date of the Report which have affected the financial position
of the Company.

Significant and Material Orders:

The Company has not received any significant or material
orders passed by any regulatory authority, court or tribunal
which may impact the going concern status and Company's
operations in future.

Reporting of Frauds by Auditors:

During the year under review, there were no frauds reported
by Auditors under Section 143(12) of the Act.

Details on Insolvency and Bankruptcy Code:

During the year under review, no application has been made
by the Company under the Insolvency and Bankruptcy Code
and accordingly the requirement of disclosing the following
details are not applicable to the Company:

(i) t he details of application made or any proceeding
pending under the Insolvency and Bankruptcy Code,
2016 (31 of 2016) during the year alongwith their status
as at the end of the financial year; and

(ii) t he details of difference between amount of the
valuation done at the time of onetime settlement and
the valuation done while taking loan from the Banks or
Financial Institutions along with the reasons thereof.

DETAILS ON INTERNAL FINANCIAL CONTROLS
RELATED TO FINANCIAL STATEMENTS

The Company has established and implemented a robust,
process-driven framework for Internal Financial Controls
(IFC) in compliance with the requirements of the Companies
Act. The Company's policies, standard operating procedures,
and control mechanisms are designed to ensure appropriate
checks and balances, thereby enabling that all transactions
are duly authorised, accurately recorded, and properly
reported.

During the year under review, the Internal Auditors with
external audit consultants evaluated the adequacy and
operating effectiveness of the Company's IFC framework.

Based on their assessment, the Board is of the opinion that
the Internal Financial Controls were adequate and operating
effectively throughout the financial year.

COMPLIANCE TO THE PROVISIONS RELATING
TO THE MATERNITY BENEFITS ACT, 1961.

During the year under review, the Company confirms that
it has duly complied with the provisions of the Maternity
Benefit Act, 1961. All eligible women employees have been
extended the statutory benefits prescribed under the Act.
The Company remains committed to fostering an inclusive
and supportive work environment that upholds the rights
and welfare of its women employees in accordance with
applicable laws.

CONSERVATION OF ENERGY, TECHNOLOGY
ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO

The information on conservation of energy, technology
absorption and foreign exchange earnings and outgo as
stipulated under Section 134(3)(m) of the Act and the Rules
framed thereunder is annexed herewith as Annexure H to
this Report.

ACKNOWLEDGEMENT

Your Directors would like to express sincere gratitude to all
valuable stakeholders of the Company viz., the Central and
State Government Departments, organizations, agencies,
our customers, shareholders, dealers, vendors, banks,
medical fraternity, patients and other business associates
for their excellent support and co-operation extended by
them during the financial year under review.

The Board of Directors also places on record its appreciation
for the significant contribution made by the employees of the
Company through their dedication, hard work and unstinted
commitment.

For and on behalf of the Board
Alkem Laboratories Limited

Basudeo N. Singh

Executive Chairman
DIN: 00760310
Mumbai, 28 May, 2026